Allo-SCT in relapsed CBF-AML: rethinking the remission requirement
Kateryna Fedorov1, Sameer Ramesh Melinkeri2, Ram Vasudevan Nampoothiri3
1Vanderbilt University Medical Center, Department of Internal Medicine, Division of Hematology and Medical Oncology, Nashville, TN, USA. Kateryna.fedorov@vumc.org.
Bone Marrow Transplantation
|June 7, 2025
Summary
No abstract available in PubMed .
More Related Videos
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
14.2K
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.5K
